Therefore, targeted inhibition of the FOXO3a/DNMT3B/MDM2 axis might be seen as a new therapeutic direction for lung cancer treatment, making the existence of the epigenetic linkage with this pathology evident. This evidence concerns the gene MDM2 and lung cancer.